Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.

This sensitization led to a highly significant ( P < 0.001) reduction in tumor size (Fig 4A ) although with limited impact on survival (Fig 4B and C ).

also in 132,142 other papers